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Based on the emergency of a severely bleeding patient,
both in spontaneous, traumatic, surgical or the obstet-
ric context, the following premises are initially proposed:
the haemorrhagic shock is a preventable cause of death,
and the severe haemorrhage could be managed in advance
when goal-directed coagulation therapy is applied at the
right time with an early re-evaluation (point of care), to
optimize the blood resources, save transfusion, minimize
morbidity, and improve patient survival (1-3). The current
demand for an optimal diagnostic tool that allows to adapt
to the urgency of a bleeding adult or paediatric (4) patient
that requires a fast and precise action in a life-threatening
situation, is forcing to act as soon as possible and in a tar-
geted manner.
Nowadays, viscoelastic monitoring of coagulation at
bedside is used worldwide as it offers the demanded char-
acteristics (5, 6) such as rapid and accurate monitoring of
clot formation and destruction, early differential diagno-
sis of coagulopathy, individualized treatment guidelines
following the decision algorithms, good reliability, and
very fast response time. There are currently 2 viscoelastic-
based coagulation technologies with wide clinical applica-
tion and sufficient scientific evidence of their effectiveness
and excellent results: thromboelastometry (ROTEM®) and
thromboelastography (TEG®).
The experience and scientific evidence of employing
viscoelastic technologies in the patients with haemor-
rhagic shock positively increased in the last decade (7-9).
The objective: to reduce or avoid the transfusion of blood
products required to reanimate severe bleeding, without
wasting them or overtransfusing the patient, saving on
economic resources and acting in the most specific way
possible.
The best way to reanimate a severe haemorrhage, in
which the risk of coagulopathy is very high, is to consider
the best resources and the easiest accessibility to them. It
is essential to know the pathophysiology of the procedure
that causes bleeding; for example, the acute trauma in-
duced coagulopathy in a severely injured patient, where
the viscoelastic approach is described in several studies
(10-12) conducted to highlight the importance of early di-
agnosis of hyperfibrinolysis, since it is directly related to
the increase of mortality. The gold standard to diagnose hy-
perfibrinolysis is viscoelastic technology. Thus, it is a fun-
damental tool to diagnose and treat acute traumatic co-
agulopathy, and also in other conditions such as liver dis-
ease (13), postpartum haemorrhage (14), or cardiac surgery
(15). The current European guidelines for management
of trauma bleeding patients (16) recommend the use of
early and repeated monitoring of coagulation, and using a
traditional laboratory test (grade 1A) and/or a viscoelastic
method (grade 1C).
The broad concept of damage control resuscitation
comes from the military setting in the context of the pa-
tient with trauma and advocates the management of se-
vere haemorrhage with the application of fixed ratios of
transfusion 1:1:1, with fresh frozen plasma as main resus-
citation fluid. But even with the last randomized control
trial with high scientific evidence (the pragmatic random-
ized optimal platelet and plasma ratios (PROPPR) Study
(17)), a totally favourable conclusion about the use of this
approach could not be fully obtained, when trying to com-
pare 1:1:1 to 1:1:2 approaches.
In common clinical practice, depending on the blood
products and prothrombotic available drugs it can be
acted following the haemostatic protocols and it is always
a matter of time and velocity to the physician who leads the
resuscitation. There are circumstances in which it is neces-
sary to transfuse very quickly and with great volume, but
at the moment when a blood sample can be extracted and
analysed in a viscoelastic method, the therapeutic guide
marked by the proof of concept (POC) technology is very
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useful, as the therapeutic efforts are directed to replace
only those haemostatic deficient components. In severe ac-
tive bleedings, the standard coagulation tests are too slow
to take fast clinical judgements (18). In addition, the results
obtained from viscoelastic methods are validated in differ-
ent studies (19).
The fundamental principle of handling these tech-
niques is that decisions of transfusion should not be
strictly made because the test results are outside a numer-
ical range of each parameter defined by the different de-
vices. Decisions will always be taken according to the clini-
cal situation of the patient and according to the availability
of treatment options (20, 21).
The therapeutic decision algorithm based on POC de-
vices should be coupled to the massive transfusion pro-
tocol approved in each hospital (22, 23).The combination
of these 2 procedures is what actually brings logic to the
resuscitation of a haemorrhagic shock and allows taking
advantage of both resources. The transfusion protocol
should develop an actuation procedure for the rapid and
organized dispensing of blood products from the blood
bank. The combination of resources should not be ob-
served as contradictory or incapable of being overlaid on
organizational issues. It is an intense multi-disciplinary
task that requires an extensive preliminary work of com-
munication so that the protocol of action is consensual
and following an ideological order. For this purpose, all
medical services involved should participate in the imple-
mentation. The development of a protocol that structures
the dispensation of hematic products is essential to ensure
immediate action if it is necessary in the emergent cases,
but it should be followed absolutely by a POC-based treat-
ment algorithm. It requires, as already mentioned, an ex-
haustive teamwork.
It is certainly difficult to apply the adult-based mas-
sive bleeding protocols to children, because the traditional
definition of massive transfusion cannot be considered
for the paediatric patients. Therefore, estimating blood
loss in mL/kg or total blood volume in children should be
considered instead of unit counts when considering mas-
sive transfusion or bleeding. Adult protocols should be
adapted to the paediatric patient, not applying the ratio-
driven formulas, but the POC algorithms above all, leav-
ing aside the conventional coagulation tests for an accu-
rate and fast resuscitation (24). It is assumed that using an
algorithm based on fixed ratios of transfusion in children
is also the failure of the strategy and there is not sufficient
evidence to support this approach at all.
A recent Cochrane revision assessed the benefits and
harms of thromboelastography or thromboelastometry-
guided transfusion in adults and children with severe
bleeding (4). They looked at different outcomes, such as
overall mortality and bleeding events, with subgroups and
sensitivity analyses, also examining the role of bias to con-
sider the evidence. The study concluded that there is grow-
ing evidence that application of POC-guided transfusion
strategies may reduce the need for blood products and im-
prove survival in patients with severe bleeding. However,
these results are primarily based on trials of elective car-
diac surgery involving cardiopulmonary bypass and the
level of evidence remains low. Therefore, further evalua-
tion of POC-guided transfusion in acute settings in low risk
bias studies is needed.
Several reports suggest that the cost of blood products
may rise over time (25). In the United States, the cost of
erythrocyte transfusion exceeds 1.3 billion dollars annually
(26). In the developing countries with limited financial re-
sources, the economic burden of transfusion is even larger
due to poorly settled hemovigilance systems. In transfu-
sion medicine, several cost-reduction strategies are intro-
duced (27). It is suggested that POC-guided transfusion
may provide the opportunity to improve quality of care,
while reducing the cost thereof. A review study revealed
that point-of-care viscoelastic testing is cost-saving and re-
sults in reduced amounts of administered blood prod-
ucts without changing the clinical outcome of patients
(3). Another recent survey in patients undergoing cardiac
surgery suggested that incorporating viscoelastic testing
into transfusion algorithms improved medical outcomes
in the presented health economic model, in comparison
with standard laboratory tests; despite the higher costs of
testing (28). Optimizing blood usage finally improves the
outcome through channelling resources toward other di-
agnostic and therapeutic initiatives.
Nowadays, there is a wide clinical experience in many
medical-surgical disciplines to use POC-guided transfu-
sion, even though the degree of evidence is not strictly de-
sirable to make a unanimous and universal recommenda-
tion. For this reason, it should be mandatory for all cen-
tres where severe acute haemorrhage is attended, to im-
plement POC technology to develop decision algorithms
for haemostatic resuscitation. This could lead to the de-
velopment of new randomized multicentre clinical trials
that reinforce the evidence on the reduction of transfusion
of blood components and, above all, the increase in sur-
vival of the patients with severe bleeding, both in adults
and children.
Once the physician attending the resuscitation of a
severe bleeding acquires the routine of combining the
initial (maybe empirical, but not necessarily ratio-driven
approach) performance with the guidelines of treatment
based on point of care haemostatic technology, the results
begin to improve, and the resources get optimized (29, 30).
Viscoelastic methods provide a rapid assessment of coag-
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ulation to support clinical decision-making, generating a
growing confidence in these methods, and increased use.
By this technology, the general impression is that patients
are treated much more specifically, accurately, and cost-
effectively with improved survival.
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